ORIGINAL RESEARCH

Is lung ultrasound score a useful tool to monitoring and handling moderate and severe COVID-19 patients in the general ward? 
An observational pilot study

Marco Baciarello1,2 · Andrea Bonetti2 · Luigi Vetrugno3 · Francesco Saturno2 · Antonio Nouvenne4 · Valentina Bellini2 · Tiziana Meschi4,5 · Elena Bignami1,2

Received: 17 December 2020 / Accepted: 14 April 2021 / Published online: 4 May 2021
© The Author(s) 2021

Abstract
Lung ultrasound is a well-established diagnostic tool in acute respiratory failure, and it has been shown to be particularly suited for the management of COVID-19-associated respiratory failure. We present exploratory analyses on the diagnostic and prognostic performance of lung ultrasound score (LUS) in general ward patients with moderate-to-severe COVID-19 pneumonia receiving O2 supplementation and/or noninvasive ventilation. From March 10 through May 1, 2020, 103 lung ultrasound exams were performed by our Forward Intensive Care Team (FICT) on 26 patients (18 males and 8 females), aged 62 (54 – 76) and with a Body Mass Index (BMI) of 30.9 (28.7 – 31.5), a median 6 (5 – 9) days after admission to the COVID-19 medical unit of the University Hospital of Parma, Italy. All patients underwent chest computed tomography (CT) the day of admission. The initial LUS was 16 (11 – 21), which did not significantly correlate with initial CT scans, probably due to rapid progression of the disease and time between CT scan on admission and first FICT evaluation; conversely, LUS was significantly correlated with PaO2/FiO2 ratio throughout patient follow-up [R = −4.82 (−6.84 to −2.80; p < 0.001)]. The area under the receiving operating characteristics curve of LUS for the diagnosis of moderate-severe disease (PaO2/FiO2 ratio ≤ 200 mmHg) was 0.73, with an optimal cutoff value of 11 (positive predictive value: 0.98; negative predictive value: 0.29). Patients who eventually needed invasive ventilation and/or died during admission had significantly higher LUS throughout their stay.

Keywords Lung Ultrasound · COVID-19 · Computed tomography · Non invasive ventilation

1 Introduction
Lung ultrasound (LU) imaging has a crucial role in the management of COVID-19-associated pneumonia [1]. Although chest tomography (CT) is the reference standard for diagnosis, LU has been shown to be useful in the pre-hospital setting [2] and upon hospital admission of COVID-19 patients [3, 4]. Respiratory COVID-19 symptoms may persist for at least 60 days in 67% of patients [5], and while repeat CT may be impractical and/or unsafe for patients and operators, LU may be the default imaging modality for monitoring patients’ condition throughout their hospital stay and, if needed, after discharge [6]. Agreement with CT seems to be more than adequate in SARS-CoV-2-related pneumonia [7, 8].

Lung ultrasound score (LUS) is a semi-quantitative model which entails the assessment of 12 regions for the presence of specific artifacts caused by increased extravascular water

* Elena Bignami
elenagiovanna.bignami@unipr.it

1 Anesthesiology, Department of Medicine and Surgery, Critical Care and Pain Medicine Division, University of Parma, Viale Gramsci 14, 43126 Parma, Italy
2 Anesthesiology and Critical Care Division, Azienda Ospedaliero-Universitaria Di Parma, Parma, Italy
3 Department of Medicine, Anesthesia and Intensive Care Clinic, University of Udine, Udine, Italy
4 Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria Di Parma, Parma, Italy
5 Department of Medicine and Surgery, University of Parma, Parma, Italy
In this study, we present the results of our analysis of consecutive cases followed by our FICT, who were monitored with repeat LUS examination as well as more conventional parameters. The aim of the study is to explore the diagnostic and prognostic usefulness of LUS in terms of risk of admission to the ICU and/or in-hospital death.

### 2 Material and methods

This was an observational retrospective pilot study aimed at comparing lung ultrasound examination, computer tomography scan and gas exchange when all exam where available. The study was approved by the Local Ethics Committee (protocol nr. 730/2020, Comitato Etico Unico per l’Area Vasta Emilia Nord). Patients were routinely asked to consent to the use of anonymized aggregate data for research purposes as part of the intake process, as customary at our institution. We checked for expressed consent in patients’ medical records; additionally, we attempted to contact survivors to discharge to confirm their consent to the use of clinical data for the present study.

As a convenience sample, we reviewed medical records of the first 30 patients followed by the FICT between March and April 2020. Indications for hospital admission included persistently high fever, \(\text{SpO}_2 \leq 92\%\) and/or \(< 90\%\) after a walk test, in the presence of signs and symptoms compatible with viral pneumonia. All patients in COVID-19 medical wards at our hospital had at least two positive polymerase chain-reaction tests for SARS-CoV-2. Patients had been referred to the FICT referral by their treating physicians due to respiratory compromise, and specifically for failure to reach and maintain a peripheral blood oxygen saturation \((\text{SpO}_2) \geq 93\%\) and/or a respiratory rate \((\text{RR}) \leq 30\) breaths per minute despite optimal therapy and \(\text{O}_2 \leq 15\) L/min through a non-rebreather mask. Referrals were followed on a regular basis by FICT physicians until clinical improvement (i.e., return to \(\text{O}_2\) supplementation \(< 15\) L/min) or terminal deterioration (withdrawal of care), or until transfer to the ICU if applicable. Consultations could result in initiation of HFNC therapy, continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV). Patients were defined as being co-managed by the FICT between the first and last assessment. In each case the decision to switch patients to NIV was based on clinical criteria including respiratory rate greater than 30 breaths per minute, dyspnea, peripheral oxygen saturation less than 91% and \(\text{PaO}_2/\text{FiO}_2\) ratio less than 200 mmHg.

#### 2.1 Lung ultrasound

Lung ultrasound examinations were performed whenever feasible in patients followed by the FICT, typically no less than once every other day. Both took almost 50% of total exams each. The scanning technique has been described before [11]; briefly, each hemithorax was divided into three regions: anterior (ventral to the anterior axillary line), middle (between the anterior and posterior axillary lines) and posterior (dorsal to the posterior axillary line); each region was further divided into an upper and lower zone by a transverse plane passing through the xyphoid process. The worst scan from each zone was scored as follows: A-lines or \(< 2\) separate B lines (normal or A-pattern, plus lung sliding), 0 points; well-spaced B lines (B-pattern, plus lung sliding), \(\geq 3\), 1 point; coalescent or fused B-lines (light beam, plus lung sliding), 2 points; lung consolidation, including multiple small subpleural consolidations, 3 points. All examinations were performed with the same device (iQ ultrasound probe, Butterfly Network, Inc., Guilford, CT, USA) and stored using the original software in a dedicated, secured cloud store system.

All FICT practitioners underwent a lung ultrasound course upon starts the resident program. Data from ultrasound examinations was recovered from the ultrasound device’s database and analyzed by two authors (A.B. and F.S.); in case of discordance, a third Author (M.B.) was asked to break the tie by convening with either assessment. All exams were performed by one of three physicians who had performed at least 25 lung ultrasound examinations [12].

On admission, all the patients routinely underwent non-contrast chest high-resolution computed tomography (HRCT), performed with either a 128-slice scanner (SOMATOM Definition Edge, Siemens Healthineers, Erlangen, Germany) or (during peak periods) an extra 16-slice truck-mounted mobile scanner (SOMATOM Emotion, Siemens Healthineers, Erlangen, Germany). Images...
were acquired with the patient in the supine position during end-inspiration breath-hold. Extent of lung involvement, as typical ground glass areas, was scored as percentage of the whole lungs, by 5% of discrete increment (range 0 to 100), while consolidations, another typical finding in SARS-CoV-2 pneumonia, were described with the aim of differentiating CT pattern compatible with organizing phenomena as opposed to other non-specific consolidation patterns.

Routine arterial blood gas (ABG) analyses were drawn in the morning, with patients maintaining on the prescribed oxygen supplementation/mechanical ventilation mode. We defined moderate-severe COVID-19 pneumonia as one leading to \( \text{PaO}_2/\text{FiO}_2 \) ratio \( \leq 200 \) mmHg; severe disease was defined by \( \text{PaO}_2/\text{FiO}_2 \leq 100 \) mmHg.

### 2.2 Statistical analysis

Data were analyzed using non-parametric and/or robust approaches and presented as median (interquartile range) or count (percentage); where applicable, 95% confidence intervals were computed using bias-corrected bootstrap approaches. A receiver operating characteristics curve was plotted for LUS as a marker of \( \text{PaO}_2/\text{FiO}_2 \) ratio \( \leq 200 \) mmHg (“moderate-severe” disease). The threshold value for LUS was selected with Youden’s J statistic. We utilized both fixed-effects and mixed (random) effects models for linear (LUS vs. CT score) and logistic regression (LUS vs. risk of composite outcome). Regression terms were added in a stepwise fashion except for the fixed effect of LUS and a random between-subject effect (as intercept), which were kept constant; a random interaction term was also tested (subject \( \times \) LUS). Regression terms were included in models if they led to a decrease in Akaike’s Information Criterion \( \geq 1 \) unit, suggesting a \( \geq 65\% \) chance of the new model reducing information loss. Analyses were run using the lme4 [13], ggeffects [14], pROC [15] and plotROC [16] packages for the R programming language [17]. A \( p \)-value \( < 0.05 \) was considered statistically significant.

### 3 Results

From March 10 through May 1, 2020, 103 lung ultrasound exams were performed on 26 patients (18 males and 8 females), aged 62 (54 – 76) and with a BMI of 30.9 (28.7 – 31.5). The median patient follow-up was 8 (6 – 9) days, with a maximum duration of 31.9 days. Table 1 describes the characteristics of included patients. Seven patients (27%) were transferred to the ICU by the FICT, where all were tracheally intubated and ventilated. Of these patients, 4 died (57%). The overall study population mortality was 11 (42%).

The first LU was performed by FICT on patients’ first evaluation, a median 6 (5 – 9) days after initial hospital admission; the initial LUS was 16 (11 – 21), and the values did not significantly correlate with admission CT scan findings (Fig. 1).

The initial ventilatory assistance mode upon FICT referral was HFNC \( \text{O}_2 \) supplementation in 22 patients; NIV was immediately initiated in the other four patients. Seven (27%) patients were eventually admitted to an ICU and received invasive mechanical ventilation (IMV). Three patients who improved to \( \text{PaO}_2/\text{FiO}_2 \) ratio > 300 mmHg immediately after ventilatory support were rapidly weaned. Figure 2 shows the relationship between LUS and \( \text{PaO}_2/\text{FiO}_2 \) throughout patients’ stays classified by type of ventilatory assistance.

A LUS score of 11 was found to have a sensitivity of 0.73 (specificity 0.95; positive predictive value: 0.98; negative predictive value: 0.29) for the diagnosis of moderate-severe disease (\( \text{PaO}_2/\text{FiO}_2 \) ratio \( \leq 200 \) mmHg); the full receiver operating characteristics curve for LUS with respect to moderate-severe COVID-19 respiratory failure is presented in Fig. 3. Values of LUS correlated with \( \text{PaO}_2/\text{FiO}_2 \) ratio throughout patient follow-up. We examined the correlation between LUS and the composite endpoint with both generalized and mixed effects logistic regression. In both cases, there was a significant correlation with \( \text{PaO}_2/\text{FiO}_2 \) ratios throughout the patients’ hospital stay. The most parsimonious and informative model according to AIC was one with fixed effects for LUS score and age, accounting for random intercepts and LUS coefficients (Table 2); the introduction of time-related terms (admission day or admission week) did not improve the model fit significantly. According to this model the \( \text{PaO}_2/\text{FiO}_2 \) ratio will decrease

### Table 1 Characteristics of included patients

| Characteristics                  | Median (IQR) | n (%) |
|----------------------------------|--------------|------|
| Age (y)                          | 62 (54, 76)  |      |
| Sex                              |              |      |
| F                                | 8 (31%)      |      |
| M                                | 18 (69%)     |      |
| Body mass index (kg·m\(^{-2}\)) | 30.9 (28.7, 31.5) |  |
| Chest CT score (%)               | 42 (26, 68)  |      |
| Length of hospital stay          | 26 (17, 35)  |      |
| Deceased during stay             | 11 (42%)     |      |
| Diabetes mellitus                | 5 (19%)      |      |
| Chronic hypertension             | 13 (50%)     |      |
| Chronic respiratory disease(s)   |              |      |
| 0                                | 25 (96%)     |      |
| 2                                | 1 (3.8%)     |      |
| Other chronic cardiovascular disease(s) |              |      |
| 0                                | 24 (92%)     |      |
| 1                                | 1 (4%)       |      |
| 2                                | 1 (4%)       |      |
| Other chronic metabolic disease(s) | 2 (7.7%)     |      |

/ Statistics presented: Median (IQR); n (%) /
approximately 3.66 mmHg for each additional LUS score point, and 1.4 mmHg for each additional year of age above the population mean at admission (Table 2). The interaction with time did not significantly improve the model (AIC: 1060, BIC: 1081). In the logistic regression model, LUS was the only significant risk factor for the composite outcome of ICU admission and/or in-hospital death; the mixed effects model, accounting for interpatient variability, was significantly more informative (20.5 vs. 28.0) but almost all of the variance was attributable to random between-subjects’ effects, which effectively voids it significance.

Patients who went on to meet the composite outcome in our study (admission to an ICU bed and/or in-hospital death) had a LUS of 20 (16 – 23) when NIV was initiated, as compared to 12 (6 – 20) in patients who did not (p = 0.013). Figure 4 summarizes LUS scores upon their first and last examination during NIV (Table 3).

4 Discussion

In March and early April 2020, Italy was the second country in the world after China to experience a surge in COVID-19 cases which overwhelmed several regional healthcare systems and led to oversaturation of ICU beds [10]. In this context, the University Hospital of Parma set up a FICT to help manage patients who were developing moderate to severe respiratory failure in medical wards and who could not immediately be admitted to ICUs, either because of borderline indications or due to temporary bed unavailability. In such a constrained-resource scenario, LUS examination has quickly become a standard feature of FICT evaluations [1], allowing to reduce the burden of disease monitoring on both patients (who could not be easily transferred to radiology suites), practitioners and the system as a whole.

The key results of this study are three: (i) in patients with COVID-19-associated pneumonia who were referred to a FICT for progressive worsening, LUS ≥ 12 points was associated with the prevalence of moderate-severe respiratory failure (AUC of the ROC curve: 0.83); (ii) a significant inverse relationship between LUS and PaO2/FiO2 ratio was found; (iii) patients who were admitted to the ICU for severe respiratory failure and/or who died during admission had higher LUS, and correspondingly lower PaO2/FiO2 ratio, irrespective of NIV use, as compared to those who did not require ICU admission and survived to discharge. Few studies have followed a population of COVID-19 patients with moderate-severe respiratory failure undergoing HFNC or NIV outside of the ICU.

Lung ultrasound may afford a semi-quantitative approach to ICU resource management, which can be integrated with other oxygenation parameters, or may substitute for data...
which are not readily available in all settings, such as arterial blood sampling and analysis. Our data show that LUS ≥ 12 is associated with moderate-severe disease; additionally, patients with negative outcome have significantly higher LUS both at the outset and end of NIV therapy outside of the ICU. Brahier et al. have recently published results of COVID-19 LUS screening the emergency department [18]. Their scoring system was different from classical LUS [19], and it was a median of 15 in patients who were eventually admitted to the ICU and/or died of respiratory failure; the AUC for the ROC when evaluating the risk of need for hospital admission in ED patients was found to be 0.77, similar to our 0.83.

The ability of LUS to anticipate clinical worsening has been proposed using a different scoring system in patients who were generally less severely affected than the ones in our study. In our population of sicker patients (mean PaO₂/FiO₂ ~ 180 mmHg, as opposed to 247 mmHg in Perrone et al.) those who went on to require invasive ventilation and/or die following NIV had significantly higher LUS than those who could remain on noninvasive assistance [20].

The absolute value of LUS in the negative outcome population of the present study [20 (16 – 23)] is quite similar to that found in studies utilizing the same scoring systems in different populations, despite the use of mechanical ventilation in the ward and in the ICU in the present study. For instance, the same scoring system was used in geriatric patients with no mention of ventilatory assistance [21] and a general population of COVID-19 patients, with or without overt respiratory failure [22]. In both cases, LUS ≥ 18 was associated with in-hospital mortality. In our opinion, this reinforces the general impression that ventilation does not modify the course of the disease.

Contrary to our previous findings and those of other authors [3, 8, 23, 24], LUS did not correlate significantly with CT score in this study population. This might be due to the different timing of CT and LU: these were performed within 24 h of admission in the cited studies, whereas in the present population LU was performed by intensivists on referral to the FICT, which happened 7 (5 – 10) days after admission. In those patients in the present series LU were performed upon their first evaluation by the FICT, which happened 7 (5 – 10) days after admission. Moreover, we postulate that the relatively low sensitivity of our threshold for detection of moderate-severe disease using LUS may be due to the presence of a second pathological mechanism

![Scatterplot of lung ultrasound scores against PaO₂/FiO₂ ratio on arterial blood gas analyses, different colors indicate types of ventilatory support. NIV noninvasive ventilation, IMV invasive ventilation](image.png)
leading to hypoxia: microvascular thrombosis, which has been described extensively in *post-mortem* studies [25, 26], and does not necessarily lead to increased extravascular lung water and, thus, is not quantifiable on LU.

Our study is primarily limited by the relatively small, retrospective cohort of patients. Retrospective data in this context may be affected by selection bias, although these patients are representative of the population of assisted by

---

**Fig. 3** Receiver operating characteristics curve for the diagnosis of PaO2/FiO2 ≤ 200 mmHg with ultrasound score: points along the curve indicate arbitrary proposed cut-offs; shaded areas represent 95% confidence intervals for the curve in those segments

**Table 2** Optimization of regression models for lung ultrasound score

| Predictors     | Linear model Estimates | CI            | p    | Mixed-effects model Estimates | CI            | p    |
|----------------|------------------------|---------------|------|-------------------------------|---------------|------|
| (Intercept)    | 285.18                 | 222.06 to 348.30 | <0.001 | 264.97                        | 179.41 to 350.53 | <0.001 |
| LUSs           | −4.82                  | −6.84 to −2.80  | <0.001 | −3.66                         | −6.15 to −1.17  | 0.004 |
| Age            | −1.43                  | −2.43 to −0.43  | 0.006  | −1.39                         | −2.61 to −0.17  | 0.025 |

Random effects

σ²

τ00 10,042.68

τ11 13.62

ρ01 −1.00

N 25

Observations 95

R²/R² adjusted 0.316/0.301

AIC 1078.783

The optimal models were found to be those including age as a fixed term, but not the hospital admission day. A linear mixed effects model accounting for intersubject variation in intercept and value of the LUS score parameter estimate, as a random effect, was found to be superior in terms of R² and AIC. AIC Akaike’s information criterion, CI 95% confidence intervals.
our FICT. In a small population, individual effects are more evident. This is reflected in our regression models including random effects (i.e., considering interindividual variations as an unpredictable factor), which show wide confidence intervals and high intraclass correlation coefficients. A larger, prospective cohort would be advisable for more significant results. Another limitation is that we did not account for interobserver variability in LU scoring, although we assume that a clear-cut scoring system and adequate operator experience may have minimized it [27].

In summary, we present results of our analyses on the clinical usefulness of LUS during a major COVID-19 outbreak, in the setting of a surge in hospital admissions and ICU overload. In patients admitted to medical wards, LUS was useful in identifying and monitoring those with persistent PaO₂/FiO₂ ≤ 200 mmHg; LUS was significantly higher in patients who were eventually transferred to the ICU for intubation and IMV and/or who died. Prospective research will hopefully improve these results and determine appropriate LUS risk thresholds, in order to improve patient care and ICU utilization.

**Funding** Open access funding provided by Università degli Studi di Parma within the CRUI-CARE Agreement.
Declarations

Conflict of interest Luigi Vetrugno received travel support for Congress Lecture by Cook Medical. The other authors declare that they have no conflicts of interest or competing interests.

Ethical approval The relevant local ethics committee (Comitato Etico Unico per l’Area Vasta Emilia Nord protocol nr. 730/2020) approved the study protocol and guaranteed its accordance with the Declaration of Helsinki.

Informed consent Patients were routinely asked to consent to the use of anonymized aggregate data for research purposes as part of the intake process, as customary at our institution. We checked for expressed consent in patients’ medical records; additionally, we attempted to contact survivors to discharge to confirm their consent to the use of clinical data for the present study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Volpicelli G, Gargani L, Perlini S, et al. Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study. Intensive Care Med. 2021;47:444–54. https://doi.org/10.1007/s00134-021-06373-7.
2. Nouvenne A, Ticinesi A, Parise A, Prati B, Esposito M, Cocchi V, Crisafulli E, Volpi A, Rossi S, Bignami EG, Baciarello M, Brianti E, Fabi M, Meschi T. Point-of-care chest ultrasonography as a diagnostic resource for COVID-19 outbreak in nursing homes. J Am Med Dir Assoc. 2020;21:919–23. https://doi.org/10.1016/j.jamda.2020.05.050.
3. Nouvenne A, Zani MD, Milanese G, Parise A, Baciarello M, Bignami EG, Odone A, Sverzellati N, Meschi T, Ticinesi A. Lung ultrasound in COVID-19 pneumonia: correlations with chest CT on hospital admission. Respiration. 2020;99:1–8. https://doi.org/10.1159/000509223.
4. Vetrugno L, Bove T, Orso D, Barbariol F, Bassi F, Boero E, Ferrari G, Kong R. Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19. Echocardiography. 2020;37:625–7. https://doi.org/10.1111/echo.14664.
5. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbou-Tournois C, Laribi S, Flamant T, Ferreira-Maldent N, Bruyère F, Stefic K, Gaudy-Graffin C, Grammatico-Guillon L, Bernard L. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.09.052.
6. Boero E, Schreiber A, Rovida S, Vetrugno L, Blaivas M. The role of lung ultrasonography in COVID-19 disease management. J Am Coll Emerg Physicians Open. 2020. https://doi.org/10.1002/emp2.12194.
7. Lopes AJ, Mafout TT, da Costa CH, Rufino R, de Cásia FM, Kirk KM, Cobo CG, da Costa HDSB, da Cruz CMBQ, Mogami R. Comparison between lung ultrasound and computed tomographic findings in patients with COVID-19 pneumonia. J Ultrasound Med. 2020. https://doi.org/10.1002/jum.15521.
8. Yang Y, Huang Y, Gao F, Yuan L, Wang Z. Lung ultrasonography versus chest CT in COVID-19 pneumonia: a two-centered retrospective comparison study from China. Intensive Care Med. 2020;46:1761–3. https://doi.org/10.1007/s00134-020-00696-1.
9. Via G, Storti E, Gulati G, Neri L, Mojoli F, Braschi A. Lung ultrasound in the ICU: from diagnostic instrument to respiratory monitoring tool. Minerva Anestesiol. 2012;78:1282–96.
10. Tonetti T, Grasselli G, Zanella A, et al. Use of critical care resources during the first 2 weeks (February 24–March 8, 2020) of the Covid-19 outbreak in Italy. Ann Intensive Care. 2020;10:133. https://doi.org/10.1186/s13613-020-00750-z.
11. Vetrugno L, Baciarello M, Bignami E, Bonetti A, Saturno F, Orso D, Girometti R, Cereser L, Bove T. “The pandemic” increase in lung ultrasound use in response to Covid-19: can we complement computed tomography findings? A narrative review. Ultrasound J. 2020;12:39. https://doi.org/10.1186/s13089-020-00185-4.
12. Rouby J-J, Arbelot C, Gao Y, et al. Training for lung ultrasound score measurement in critically Ill patients. Am J Respir Crit Care Med. 2018;198:398–401. https://doi.org/10.1164/rccm.201802-0227te.
13. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Statist Software. 2015. https://doi.org/10.18637/jss.v067.i01.
14. Lüdecke D. ggplot2: tidy data frames of marginal effects from regression models. J Open Source Software. 2018. https://doi.org/10.21105/joss.00772.
15. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. https://doi.org/10.1186/1471-2105-12-77.
16. Sachs MC, plotROC: a tool for plotting ROC curves. J Statist Software. 2017. https://doi.org/10.18637/jss.v079.c02.
17. The R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
18. Brahier T, Meuwly JY, Pantet O, Brochu Vez MJ, Gerhard Donnet H, Hartley MA, Hugli O, Boilat-Blanco N. Lung ultrasonography for risk stratification in patients with COVID-19: a prospective observational cohort study. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1408.
19. Soldati G, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, Perlini S, Torri E, Mariani A, Miosolani EE, Tursi F, Mento F, Demi L. Proposal for international standardization of the use of lung ultrasound for patients with COVID-19: a simple, quantitative, reproducible method. J Ultrasound Med. 2020;39:1413–9. https://doi.org/10.1002/jum.15285.
20. Perrone T, Soldati G, Padovini L, Fiengo A, Lettieri G, Sabatini U, Gori L, Lepore F, Garoli M, Palumbo I, Inchingolo R, Smargiassi A, Demi L, Miosolani EE, Tursi F, Klersy C, Di Sabatino A. A new lung ultrasound protocol able to predict worsening in patients affected by severe acute respiratory syndrome coronavirus 2 pneumonia. J Ultrasound Med. 2020. https://doi.org/10.1002/jum.15548.
21. Recinella G, Marasco G, Tufoni M, Brizzi M, Evangelisti E, Maestri L, Fusconi M, Calogero P, Magalotti D, Zoli M. Clinical role of lung ultrasound for the diagnosis and prognosis of coronavirus disease pneumonia in elderly patients: a pivotal study. Gerontology. 2020. https://doi.org/10.1159/0000512090.
22. Lichter Y, Topilsky Y, Taieb P, Banai A, Hochstadt A, Merdler I, Gal Oz A, Vine J, Goren O, Cohen B, Sapir O, Granot Y, Mann T, Friedman S, Angel Y, Adi N, Laufer-Perl M, Ingber M, Arbel Y, Matot I, Szekely Y. Lung ultrasound predicts clinical course and outcomes in COVID-19 patients. Intensive Care Med. 2020;46:1873–83. https://doi.org/10.1007/s00134-020-06212-1.

23. Ottaviani S, Franc M, Ebstein E, Demaria L, Lheure C, Debray MP, Khalil A, Crestani B, Borie R, Dieudé P. Lung ultrasonography in patients with COVID-19: comparison with CT. Clin Radiol. 2020;75:877.e1-877.e6. https://doi.org/10.1016/j.crad.2020.07.024.

24. Tung-Chen Y, Martí de Gracia M, Díez-Tascón A, Alonso-González R, Agudo-Fernández S, Parra-Gordo ML, Ossaba-Vélez S, Rodríguez-Fuertes P, Llamas-Fuentes R. Correlation between chest computed tomography and lung ultrasonography in patients with coronavirus disease 2019 (COVID-19). Ultrasound Med Biol. 2020;46:2918–26. https://doi.org/10.1016/j.ultrasmedbio.2020.07.003.

25. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, Rech R, Colombo R, Antinori S, Corbellino M, Galli M, Catena E, Tosoni A, Gianatti A, Nebuloni M. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135–40. https://doi.org/10.1016/S1473-3099(20)30434-5.

26. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, Muenchhoff M, Hellmuth JC, Ledderose S, Schulz H, Scherer C, Rudelius M, Zoller M, Höchter D, Keppler O, Teupser D, Zwißler B, von Bergwelt-Baldon M, Kääb S, Massberg S, Pekayvaz K, Stark K. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142:1176–89. https://doi.org/10.1161/CIRCULATIONAHA.120.048488.

27. Arbelot C, Dexheimer Neto FL, Gao Y, Brisson H, Chunyao W, Lv J, Valente Barbas CS, Perbet S, Prior Caltabellotta F, Gay F, Deransy R, Lima EJS, Cebey A, Monsel A, Neves J, Zhang M, Bin D, An Y, Malbouisson L, Salluh J, Constantin JM, Rouby JJ, APECHO SG. Lung ultrasound in emergency and critically Ill patients: number of supervised exams to reach basic competence. Anesthesiology. 2020;132:899–907. https://doi.org/10.1097/ALN.0000000000003096.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.